[BRAF mutation: a novel approach in targeted melanoma therapy]

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Malignant melanoma incidence is rising globally, posing significant therapeutic challenges, especially in advanced stages.
• While surgery is effective for locally advanced disease, metastatic melanoma remains difficult to treat.
• Advances in understanding melanoma's molecular landscape reveal it's a heterogeneous disease with distinct subtypes.

Purpose of the Study:

• To highlight the evolving treatment landscape for malignant melanoma.
• To discuss the impact of molecular subtyping on therapeutic strategies.
• To introduce novel targeted therapies and immunotherapies for advanced melanoma.

Main Methods:

• Review of current research on melanoma molecular alterations.
• Analysis of targeted therapies based on specific mutations (e.g., C-KIT, BRAF).
• Discussion of immunotherapies targeting immune checkpoints like CTLA-4.

Main Results:

• BRAF V600E mutations predict response to BRAF kinase inhibitors like vemurafenib.
• C-KIT mutations indicate sensitivity to C-KIT kinase inhibitors such as imatinib.
• Ipilimumab, an antibody targeting CTLA-4, enhances anti-tumor T-cell activity in metastatic melanoma.

Conclusions:

• Personalized medicine approaches based on molecular profiling are transforming melanoma treatment.
• Targeted therapies and immunotherapies represent significant progress in managing advanced melanoma.
• Continued research into melanoma subtypes and immune regulation is crucial for further therapeutic advancements.